Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966883 · ClinicalTrials.gov registry record
SpermQT Prospective Observational Trial
A clinical trial of Male Infertility, sponsored by Inherent Biosciences.
- Active
- Registry status
- 1,000
- Enrollment target
- 6
- Study locations
NCT05966883: Active study of Male Infertility, sponsored by Inherent Biosciences.
NCT05966883 is a study of Male Infertility that is active but no longer recruiting, run by Inherent Biosciences. The registered enrollment target is 1,000 participants, above the 433-participant average among 8 other Male Infertility trials with a reported enrollment target (131% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05966883, a study of Male Infertility, is active but no longer recruiting, sponsored by Inherent Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of the study is to validate the ability of the Epigenetic Sperm Quality Test (SpermQT) to assess a man's sperm quality and corresponding success of infertility treatments.
Primary Outcome
Number of patients that have and have not achieved pregnancy during rounds 1 and 2 of IUI in each bracket of SpermQT score (Poor, Normal, and Excellent)
Conditions Studied
Study Locations (6)
California
- Male Fertility and Sexual Medicine Specialists - San Diego
Colorado
- Shady Grove Fertility - Greenwood Village
Connecticut
- Yale Medicine - Orange
Massachusetts
- Boston IVF - Waltham
Texas
- Inception Fertility, LLC - Houston
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2026-09-30 |
What the registry record for NCT05966883 still lists
NCT05966883 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 433-participant average among 8 other Male Infertility trials with a reported enrollment target (131% higher).
The record links to 1 condition, with Male Infertility appearing as the primary indexed condition, and to 0 interventions.
NCT05966883 lists 6 locations in 6 states (California, Colorado, Connecticut).
Frequently Asked Questions
What is clinical trial NCT05966883 about?
NCT05966883 is a clinical study titled "SpermQT Prospective Observational Trial". The goal of the study is to validate the ability of the Epigenetic Sperm Quality Test (SpermQT) to assess a man's sperm quality and corresponding success of infertility treatments.
What is the current status of trial NCT05966883?
This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2023-01-01. Estimated completion is 2026-09-30.
What conditions does trial NCT05966883 study?
This clinical trial studies the following conditions: Male Infertility.
Who is sponsoring clinical trial NCT05966883?
This trial is sponsored by Inherent Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05966883 being conducted?
This trial has 6 study locations across California, Colorado, Connecticut, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Male Infertility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05966883's enrollment target sits among peer trials
1,000 2nd of 8 higher than 6 of 8 other Male Infertility trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Male Infertility trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Platelet Rich Plasma Testis Treatment for Infertile Men
RECRUITING · NA
-
Male Infertility and Assisted Reproductive Technologies Research Biobank
RECRUITING
-
Home Semen Testing in Men Beginning Attempts to Conceive
ACTIVE NOT RECRUITING · NA
-
To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That Develop to the Point That They Are Able to be Transferred) in IVF Cycles.
ACTIVE NOT RECRUITING · NA
-
A Pilot Study to Evaluate the Effect of Pomegranate Juice on Semen Parameters in Healthy Male Volunteers
COMPLETED · Phase 1
-
Small RNA Pathways in Mammalian Gametogenesis
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI